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Abstract 
 
Objective(s)  
There are some reports that the teratogenic effects of cyclophosphamide (CPA) can be prevented by 
application of antioxidant drugs and stimulation of the maternal immune system. Echinacea purpurea extract 
is antioxidative and immunomodulator drug. Mesna (Sodium 2-mercaptoethane sulfonate) is used for 
decreasing side effects of CPA, especially hemorrhagic cystitis.  In this study, we compared the prophylactic 
effects of mesna and Echinacea extract on teratogenic effects of CPA.  
Materials and Methods  
This study was performed on 32 pregnant rats that were divided into 4 groups. The first group (control 
group) received normal saline and the other groups received CPA (15 mg/kg intraperitoneally) on 13th day 
of gestation. Mesna and E. purpurea extracts were administrated at doses of 100 and 400 mg/kg by IP 
injection, respectively, along with it and 12 hr later, after CPA injection. Rats were dissected on day 20 of 
gestation, embryos harvested and after determination of gross malformations they were stained by Alizarin 
red-Alcian blue method.  
Results 
Cleft palate incidence was 38.46, 30.77 and 14.28% in fetuses of rats that received only CPA, CPA with 
mesna and CPA with Echinacea extract, respectively. In addition, skeletal anomalies incidence including 
limbs, vertebra, sternum, and scapula defects were decreased by Echinacea extract. 
Conclusion 
E. purpurea has significant effect on preventing CPA-induced malformations and better prophylactic effect 
than mesna on cases like CPA-induced cleft palate.  
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Introduction 
Some chemical agents and drugs can induce 
teratogenic effects and abortion (1). 
Developmental defects are a major health 
problem as in the USA 3-5% of fetuses have 
congenital abnormality (2). It is estimated that 
7-10% of human anatomic anomalies result 
from the disruptive actions of drugs, viruses, 
and other environmental factors (3). De 
Sanntis  et al also estimated that defects 
attributable to drug therapy represent about 1% 
of congenital defects of known etiology (4). 
Although, 40 agents are teratogenic for human 
fetuses, more agents are teratogenic in 
laboratory animals. Valperoic acid, 
cyclophosphamide (CPA), methylnitrous urea 
and phenytoin are the best known teratogenic 
drugs in human and laboratory animals (5, 6). 
Several studies show that the stimulation of 
maternal immune system can decrease or 
prevent drug-induced embryonic abnormalities 
(7, 8). For example, in one study, macrophage 
activation decreases incidence of cleft palate 
and digital and tail anomalies in fetuses of 
mice that received urethane and methylnitrous 
urea (8). In another study, interferon gamma 
reduced urethane-induced cleft palate and 
granulocyte-colony stimulating factor 
decreased cyclophosphamide-induced distal 
limb abnormalities in mice (9). 
Data from laboratory research and critical 
trials also suggest beneficial influences of the 
maternal immune system on pregnancy 
outcome (10, 11). Nonspecific immune 
stimulation by injection of Freund's complete 
adjuvant (FCA) reduced early embryo loss in 
CBA/J mice (10). In rodents (12) and humans 
(11), alloimmunization with paternal 
lymphocytes has reported efficacy for 
prevention of early embryo loss. In teratogen-
exposed rodents, a significant decrease in 
morphologic defects was observed after 
maternal immune stimulation (13). Mechanism 
for these effects remains unclear; however, the 
possible involvement of cytokines produced 
by immune cells has been suggested (13). 
Ivnitsky  et al (1998) found that CPA- 
induced brain and craniofacial anomalies in 
mice were associated with increased TNF-α in 
fetal head and brain (14). Maternal 
immunostimulation decreased severity of 
CPA-induced malformation in these mice, and 
decreased TNF- α expression in fetal heads 
(14). In related studies, Savion et al (1999) 
reported that maternal dosing with granulocyte 
macrophage-colony  stimulating  factor           
(GM-CSF) significantly reduced CPA-induced 
limb malformation in mice. This effect was 
comparable to that produced by intrauterine 
leukocyte administration, and resulted in 
increased maternal IL-2 and IL-3 production 
as well as increased Mac-1 positive leukocyte 
in the uteroplacental units of pregnant mice. 
Thus, for CPA-induced fetal malformations, 
immune-mediated protective effects have been 
related to altered levels of cytokines in both 
the uteroplacental unit and in the fetus (15). 
CPA as an alkylating agent is used for 
treatment of cancer and to prevent rejection of 
tissue transplantation. CPA has several toxic 
effects including hemorrhagic cystitis. 
Metabolites of CPA, especially acroleine 
modulates its toxic effects (16).  
 Mesna (sodium 2-mercaptoethane sulfonate) 
is used for decreasing toxic effects of CPA in 
patients. In addition, mesna was effective in 
lowering CPA-induced malformation in rats 
(17).  
Echinacea stimulates the immune system 
and is applied in the prevention or treatment of 
some diseases including influenza and 
common cold. Echinacea extract activates 
macrophage, polymorphonuclear leukocytes 
and natural killer cells (18). The effect of 
Echinacea purpurea extract on decreasing 
phenytoin-induced cleft palate in mice was 
reported (19). 
In the present study, the prophylactic effects 
of mesna and E. purpurea extract on CPA-
induced macroscopic fetal defects in rats were 
compared. 
 
Materials and methods 
Dried aerial parts of E. Purpurea were from 
Goldaruo Co. Isfahan, Iran. The plant was 
taxonomically identified at the Department of 
Botany, School of Agriculture, Shahid 
Chamran University, Ahwaz, Iran. The plant 
was powdered, using a grinder (MSE, 
England). One hundred grams of this powder  
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was placed in a beaker and 1000 ml of 70% 
ethanol added. The mixture was left at room 
temperature for 3 days. The extract separated 
and the remaining plant extracted with more 
ethanol after 2 days. The extract was filtered 
by Whattman (No. 1) filter paper and 
concentrated under vacuum evaporation and 
then the product dried in oven at low 
temperature . 
Male and female healthy Wistar rats, 10-12 
weeks of age, weighing 180-200 g were 
purchased (Razi Institute, Karaj, Iran) and 
housed individually (males) or at 10 per 
polycarbonate cage (female) for a 2-week 
acclimation period. Rats were fed ad libitum 
by standard laboratory pellet (Pars khorakdam, 
Shoshtar, Iran.) and tap water. A 12-hr light: 
12-hr dark cycle was maintained. Room 
temperature was at 23±2 
◦C with a relative 
humidity of 45-55%. 
Male and female rats were housed together. 
Pregnant females were divided into four 
groups (n=8) and treated as follow: 
First  group  received  normal  saline                  
(10 ml/kg), the second group received CPA 
(15 mg/kg) (Slott and Hales, 1986), the third 
group received CPA (15 mg/kg) and along 
with it and 12 hr later mesna (100 mg/kg) (17), 
and the fourth group received CPA (15 mg/kg) 
and along with it and 12 hours later extract of 
E. purpurea (400 mg/kg) (19). All drugs were 
diluted in distilled water then administrated 
intraperitoneally. 
The animals were sacrificed by cervical 
dislocation on 20th day of gestation and 
fetuses collected and numbered; then weight 
and length of them measured and gross 
malformations determined. Fetuses were 
stained by Alizarin red-Alcian blue method 
(20) and investigated by stereomicroscope 
(Nikon, Japan) for skeletal defects. The 
incidence of macroscopic defects was 
determined and was compared in the groups. 
Statistical significance between groups 
determined using SPSS program. The 
minimum level of significance was P<0.05. 
 
Results 
There were not any aborted or absorbed 
fetuses from normal saline group. Total 
number of collected fetuses from groups 1, 2, 
3 and 4 were 26, 49, 27 and 47, respectively.  
No macroscopic anomalies were observed in 
the control animals. In the  control group 
palatal closures of fetuses were normal on 
gestational day 20 (i.e., palatal shelves had 
grown vertically on the sides of the tongue, 
then  horizontally  to  meet  and  fuse)            
(Figure 1A). CPA induced cleft palate at 
38.46% incidence (Figure 1B). Mesna reduced 
incidence of CPA-induced cleft palate to 
30.77%, but E. purpurea extract reduced it to 
14.28 %. In group 2, percentage of intrauterine 
death of fetuses was 32.6%, but not in other 
groups. Percentages of absorbed fetuses were 
40.8, 51.85 and 55.3 in groups 2 to 4, 
respectively, so mesna and E. purpurea 
increased the resorption rate. 
 
 
 
 Figure 1. Ventral  view of  skull of GD  20 fetal  rats.          
A) Normal palatine bone B) Cleft palate induced by 
cyclophosphamide (arrow) which stained with Alizarine 
red- Alcian blue. PS: palatine; BS: sphenoid.  
 
Exencephaly, omphalocele, open eye, 
brachygnathia, and several different anomalies 
in vertebrae, sternum, scapula and limbs were 
observed (Figure 2) which their incidences are 
shown in Table 1. Their incidences (except 
exencephaly) were decreased by Echinacea 
extracts. Open eye and brachgnathia were not 
observed in animals treated with mesna and E. 
purpurea.  Mean weight (P<0.043) and length 
(P<0.02) were significantly decreased in the 
group which received only CPA. The means of 
weight (P<0.044) in the group that received 
mesna were significantly greater than the 
group received only CPA. 
A B 
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Figure 2. Some skeletal defects in fetuses of rats. Curved spine of scapula and absence deltoid tuberosity (up-left); fused 
sternebrae and split xiphoid process (up-middle); curved fibula (up-right); fetus deformity (left-down); exencephaly and 
omphalocele.  
 
 
The mean weight and length in the group 
that received mesna did not differ significantly 
with the control group. The mean weight 
(P<0.049) and length (P<0.001) were 
significantly decreased in the group which 
received  Echinacea extract and differed 
significantly in comparison to the control 
group (Figures 3, 4). 
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Figure 3. Weight (mean±SEM) of fetuses in normal 
saline and test groups: 1: normal saline (1 ml/100g IP); 
2: CPA (15 mg/kg IP); 3: CPA+mesna (100 mg/kg IP); 
4: CPA+Echinacea (400 mg/kg IP). n=8;* Significant 
difference with normal saline group (P<0.05).  
Table 1. Incidence of anomalies in fetuses of groups. 
Group1 (control) without macroscopic anomalies; 
Group 2 received cyclophosphamide; group 3 received 
CPA+mesna; group 4 received CPA+Echinacea extract. 
 
Incidence (%)   
Anomaly  Group 2  Group 3  Group 4 
Cleft palate  38.46  30.77  14.28 
Exencephaly 100 92.3 100 
Omphalocele 23.07 7.69  4.76 
Open eye  23.07  84.6  0 
Brachygnathia 23.07  53.8  0 
Sternum defects  37.93  53.8  33.3 
Vertebral defects  65.5  100  61.9 
Limbs defects  100  100  76.19 
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Figure 4. Length (mean± SE) of fetuses in normal saline 
and test groups. 1: normal saline (1ml/100g IP); 2: CPA 
(15 mg/kg IP); 3: CPA+mesna (100 mg/kg IP); 4: 
CPA+Echinacea (400 mg/kg IP). n=8;* Significant 
difference with normal saline group (P<0.05).   
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Discussion 
Several studies have verified that the maternal 
immune stimulation can reduce teratogenic 
anomalies (21). Mechanisms of this effect 
remain unclear, but it is thought the fetal gene 
expression has been modulated (8). 
The enhancing antioxidative effects can 
protect fetuses against phenytoin teratogenicity 
(9, 22). Sharova et al showed that interferon-
gamma and Freund's complete adjuvant 
reduced severity of the urethane-induced cleft 
palate in mice (23). In the present study, the 
prophylactic effects of mesna and Echinacea 
on CPA-induced macroscopic fetal defects 
were compared in rats. Both mesna and 
Echinacea reduced the severity of incidence of 
cleft palate. Echinacea was greater in 
decreasing the incidence of cleft palate than 
mesna. Mesna had better protective effect than 
Echinacea on weight and length of fetuses.  
Sloth and Hales (1986) evaluated effect of 
mesna on CPA–induced teratogenicity. They 
used CPA at dose 10 and 15 mg/kg in rats in 
13th day of gestation. They observed the CPA 
can produces teratogenicity in 50 and 100% of 
fetuses with 10 and 15 mg/kg, respectively 
(17). They determined fetal defects similar 
with our study including hydrocephaly, 
omphalocele, open eye, brachygnathia, and 
limb defects. These anomalies were decreased 
by 30 mg/kg mesna. 
Cytokines have been reported to mediate 
CPA–induced neurotoxicity (7). Granulocyte-
macrophage colony stimulating factor (GM-
CSF) as cytokine and injection of leukocytes 
decreased CPA–induced teratogenicity 
including limb defects (7, 8). 
E. purpurea stimulates various immune cells 
including macrophages and natural killer cells. 
It has anti-inflammatory effects (18). In one 
study,  E. purpurea root increased levels of 
interlukine l and 6, tumor necrosing factor and 
antibody production more than the extracts 
of  E. angustifolia and E. pallida (24). 
Bukovsky et al (1995) reported that ethanolic 
extract of E. purpurea increased activity of 
mouse peritoneal macrophage following 5 
days exposure (25). In one double- blinded 
study in 24 men, oral administration of E. 
purpurea extract increased polymorphonuclear 
(PMN) phagocytic activity for 5 days that 
reached its peak levels on the 5th day (18). 
Moreover,  Echinacea h a s               a n t i -
oxidative and free-radical scavenging activity 
(26). Echinacea is used for treatment of acute 
upper respiratory infections including common 
cold and influenza (18, 27). In other study, 
Echinacea appears to attenuate the response of 
macrophages to an immune stimulus and its 
combination of phytochemicals exhibits 
different pharmacological properties to one or 
more of the isolated major individual 
components (28). Echinacea alkylamides 
modulate induced immune responses in T-cells 
(29). 
 
Conclusion  
In the present study, E. purpurea extract had 
prophylactic effect on incidence of CPA-
induced skeletal anomalies. Mesna chelates 
metabolites of CPA including acroleine and 
reduces its side effects. Effect of CPA on 
teratogenicity is mediated indirectly by 
inducing oxidative stress. Thus, E. purpurea 
can decrease anomalies from CPA by 
antioxidative or immunostimulant effect, 
which we believe deserves further 
investigation.  
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